Key facts
- This page summarizes CSL LTD's Form 3 filing for Cara Therapeutics, Inc. (TVRD).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 25 Jul 2023, 16:13.
CSL LTD - 09 Aug 2022 Form 3 Insider Report for Cara Therapeutics, Inc. (TVRD)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TVRD
- Reported as of
- 09 Aug 2022
- Net transaction value
- $0
- Reporting owner signature
- CSL LIMITED, By: /s/ Fiona Mead, Name: Fiona Mead, Title: Company Secretary
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
CSL LTD filed Form 3 for Cara Therapeutics, Inc. (TVRD) on 25 Jul 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CARA
holding
Common Stock, par value $0.001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,396,770
- Date
- 09 Aug 2022
- Ownership
- See Notes
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
CSL Limited, an Australian public limited company ("CSL"), may be deemed to have a pecuniary interest in securities reported by it on this Form 3 (the "Subject Securities").
Footnote F2
CSL's beneficial ownership of the Subject Securities is being reported solely because CSL may be deemed to beneficially own the Subject Securities as a result of its acquisition, indirectly, of 100% of the equity interests in Vifor Pharma Ltd. ("Vifor Pharma"), and, in turn, 100% of the equity interests in the entity that holds the Subject Securities, Vifor (International) Ltd. ("Vifor (International)"), and 55% of the equity interests in Vifor Fresenius Medical Care Renal Pharma Ltd. ("VFMCRP"), which were indirectly owned by Vifor Pharma, on August 9, 2022. VFMCRP may be deemed to beneficially own 6,221,943 of the Subject Securities as a result of its right to acquire such Subject Securities upon exercise of an option granted to it by Vifor (International).
Footnote F3
(Continued from Footnote 2) As a result of the merger of Vifor Pharma into Vifor Pharma Participations Ltd. ("Vifor Participations") pursuant to a merger agreement, dated May 11, 2023, CSL indirectly owns 100% of the equity interests in Vifor (International) and 55% of the equity interests in VFMCRP through its indirect ownership of 100% of the equity interests in Vifor Participations.
Footnote F4
CSL disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.